Riskpilot← Back to searchSign inGet full accessMS-OMICS ApS
APSActiveCVR 36070374Bygstubben 9Engineering activities and related technical consultancy · NACE 7112Est. 201415 employeeswww.msomics.com
Revenue 2025
DKK 16,8M
-4% vs 2024
EBITDA margin
41.9%
-7% vs 2024
Equity ratio
17.5%
Financial strength
Net profit 2025
DKK 807K
-66% vs 2024
| Revenue | DKK 16,8M | -4% |
| EBITDA | DKK 7M | -7% |
| Net profit | DKK 807K | -66% |
| Total assets | DKK 18,1M | -5% |
| Equity | DKK 3,2M | +34% |
| Employees | 15 | — |
Legal name
MS-OMICS ApS
CVR number
36070374
Legal form
Anpartsselskab
NACE code
7112 · Engineering activities and related technical consultancy
Founded
22. august 2014
Share capital
DKK 76.390
Employees
15 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør i forening med et bestyrelsesmedlem eller af to bestyrelsesmedlemmer i forening.
Company purpose
Selskabets formål er at drive bioteknisk virksomhed, herunder teknisk rådgivning om og analyse af biologiske prøver samt dermed beslægtet virksomhed.
Address
Bygstubben 9
Phone
+4553771255
Email
md@ms-omics.com
Website
www.msomics.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | -215 | 686 | 1.012 | 1.299 | 2.646 | 3.454 | 7.342 | 10.714 | 15.391 | 17.474 | 16.799 |
| Staff expenses | -672 | -532 | -749 | -1.738 | -1.708 | -3.282 | -4.963 | -7.432 | -9.605 | -9.905 | -9.765 |
| EBITDA | -887 | 155 | 262 | -439 | 937 | 97 | 2.379 | 3.282 | 5.786 | 7.569 | 7.034 |
| Depreciation & amort. | -0 | -0 | 45 | -334 | -702 | -993 | -1.521 | -2.703 | -4.192 | -4.441 | -4.310 |
| EBIT | -887 | 155 | 217 | -772 | 236 | -896 | 858 | 578 | 1.595 | 3.128 | 2.724 |
| Net financials | -30 | -26 | -34 | -173 | -281 | -371 | -439 | -825 | -1.147 | -928 | -769 |
| Profit before tax | -917 | 129 | 183 | -945 | -45 | -1.267 | 419 | -247 | 448 | 2.199 | 1.956 |
| Tax | -0 | -0 | 37 | -0 | -0 | -0 | -0 | -92 | 25 | -142 | 1.149 |
| Net profit | -917 | 129 | 146 | -945 | -45 | -1.267 | 419 | -155 | 423 | 2.342 | 807 |
| Item | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 51 | 436 | 955 | 5.738 | 6.398 | 11.048 | 10.962 | 19.943 | 18.691 | 19.095 | 18.137 |
| Equity | -867 | -738 | -591 | 463 | 418 | -349 | 70 | -402 | 22 | 2.363 | 3.170 |
| Long-term debt | 835 | 862 | 907 | 4.318 | 4.599 | 7.798 | 7.174 | 9.779 | 6.226 | 4.691 | 3.012 |
| Short-term debt | 84 | 312 | 639 | 957 | 1.380 | 3.599 | 3.717 | 10.566 | 12.443 | 12.040 | 11.293 |
| Total debt | 919 | 1.174 | 1.546 | 5.275 | 5.980 | 11.398 | 10.892 | 20.345 | 18.669 | 16.732 | 14.305 |
EBITDA margin
41.9%
This company
15.8%
Market median
+165% vs market
20152025
Equity ratio
17.5%
This company
38.2%
Market median
-54% vs market
20152025
Return on equity
25.5%
This company
18.4%
Market median
+39% vs market
20152025
Net profit margin
4.8%
This company
8.1%
Market median
-41% vs market
20152025
Asset turnover
0.93×
This company
1.12×
Market median
+17% vs market
20152025
Debt / equity
4.72×
This company
0.62×
Market median
-661% vs market
20152025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2014-08-22 – 2015-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MD Management | Management | 2014 | — | — |
NC Founder | Founder | 2014 | — | — |
AM Management | Management | 2026 | — | — |
LG Founder | Founder | 2014 | — | — |
RB Founder | Founder | 2014 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2014 | — | — | |
| Board of Directors | 2019 | — | — | |
| Board of Directors | 2022 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2022 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Clinical-Microbiomics A/S | Company | 100.0% | 100.0% | 2022 |
MS-OMICS ApS | Company | 100.0% | 100.0% | 2022 |
Ledertoug Holding ApS | Company | 10.0% | 10.0% | 2021 |
JOST JENSEN & THOMASEN HOLDING A/S | Company | 15.0% | 15.0% | 2018 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MANJIN ApS
MS-OMICS ApS Board members of MS-OMICS ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Morten Danielsen | Management | 0 companies |
| Nils Christian Ledertoug | Founder | 0 companies |
| Anders Mohr Christensen | Management | 0 companies |
| Lea Giørtz Johnsen | Founder | 0 companies |
| Rolf Burmann Ledertoug | Founder | 0 companies |
| Jacob Reinholdt Rasmussen | Board of Directors | 0 companies |
| Torben Thomasen | Board of Directors | 0 companies |
| Henrik Bjørn Nielsen | Board of Directors | 0 companies |
| Anders Christian Neto de Sousa Grøn | Chairman | 0 companies |
| Henrik Knudsen | Board of Directors | 0 companies |
| Manoj Nirmal Dadlani | Board of Directors | 0 companies |